Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Hyuralonic acid (Hyacyst®)
Ibandronic acid injection
Ibrutinib	TA429 - Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation TA491 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia TA502 - Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibuprofen (PEDA injection)
Icatibant (Firazyr®)		NHS England commissioned
Ichthammol 1% w/w and zinc oxide 15% w/w in Yellow Soft Paraffin		Unlicensed special
Idarubicin capsules
Idarubicin injection		For hospital use only
Idarucizumab 2.5g/250ml solution for injection/infusion		When rapid reversal of Dabigatran anticoagulant effect is required
Idelalisib (Zydelig)	TA359 - Idelalisib for treating chronic lymphocytic leukaemia

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.